Investments
44Portfolio Exits
2Funds
1About Prometheus Capital
Prometheus Capital is a private equity fund with a focus on investments in China companies. The Firm invests mainly in start-up and growth-stage companies which have the potential to become leaders of their own sectors, excluding real estate, infrastructure, and mining sectors. Prometheus Capital is committed to providing professional support and assistance to all their investee companies to accelerate their growth and reach their new peaks. The Firm's focused sectors include but are not limited to energy conservation and environment protection, new material, clean-tech, medical devices and service, retail & consumer, modern agriculture, and high-end manufacturing.
Prometheus Capital Headquarter Location
1605 A Block, Wanda Plaza 93 Jianguo Road, Chaoyang District
Beijing, Beijing,
China
Latest Prometheus Capital News
Apr 19, 2022
Wang Sicong (Source: Sohu) The stock price of traditional Chinese medicine-maker Yiling Pharmaceutical plunged after Wang Sicong, founder of Prometheus Capital and director of Wanda Group , reposted a video on April 14 on Weibo that questioned whether the World Health Organization had ever recommended the firm’s Lianhua Qingwen capsules as Covid-19 treatment. Wang commented on the original post: “The China Securities Regulatory Commission should strictly investigate Yiling Pharmaceutical. It’s difficult to see a media outlet that is so rigorous daring to verify and tell the truth in China.” However, on Tuesday, Wang’s Weibo account was blocked and no more posts were available. Yiling Pharmaceutical responded to Wang’s comment later in the day: “Please point out the specific problems and sources of the news and we will provide answers. From clinical trials to specific experimental data, to being included in Covid’s diagnosis and treatment plan, we have complete evidence and reports for the public.” “We have never said on any occasion that the WHO had recommended the drug as Covid-19 treatment,” the drug maker added. Yiling Pharmaceutical was established in 1992 and mainly engages in the research and development, production and sales of traditional Chinese medicine. In 2019, before the outbreak of the pandemic, its largest revenue source was cardiovascular and cerebrovascular medicine, accounting for 53.15% of the total revenue. After the outbreak in 2020, respiratory medicine represented by the Lianhua Qingwen capsules became the company’s largest revenue source. The drug’s revenue increased from 1.703 billion yuan ($266.6 million) in 2019 to 4.255 billion yuan in 2020, an increase of 149.89% year-on-year, accounting for 48.46% of the total revenue. The capsules also promoted the performance growth of Yiling Pharmaceutical. In the first three quarters of 2021, the company’s revenue topped 8.11 billion yuan while its net profit reached 1.224 billion yuan. The stock price of Yiling Pharmaceutical has also fluctuated with the ebb and flow of the trending topic concerning the company. On April 15th, its shares hit limit down and saw a 6.7 billion yuan of market value lost in one day. Only ten minutes after the market opened again on Tuesday did the company’s share price began to rise, with the highest increase rate of 4.2% to 33.75 yuan per share. Spread the love:
Prometheus Capital Investments
44 Investments
Prometheus Capital has made 44 investments. Their latest investment was in Poke Erchu as part of their Private Equity on January 1, 2022.
Prometheus Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
1/27/2022 | Private Equity | Poke Erchu | Yes | 1 | ||
1/26/2022 | Seed | Poke Culture | Yes | 1 | ||
11/23/2021 | Series C - III | Rescale | $50M | Yes | 5 | |
9/14/2021 | Private Equity | |||||
11/11/2019 | Series B |
Date | 1/27/2022 | 1/26/2022 | 11/23/2021 | 9/14/2021 | 11/11/2019 |
---|---|---|---|---|---|
Round | Private Equity | Seed | Series C - III | Private Equity | Series B |
Company | Poke Erchu | Poke Culture | Rescale | ||
Amount | $50M | ||||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 1 | 5 |
Prometheus Capital Portfolio Exits
2 Portfolio Exits
Prometheus Capital has 2 portfolio exits. Their latest portfolio exit was Niupu on March 29, 2021.
Prometheus Capital Fund History
1 Fund History
Prometheus Capital has 1 fund, including Opportune Capital Fund I.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
Opportune Capital Fund I | $4.31M | 1 |
Closing Date | |
---|---|
Fund | Opportune Capital Fund I |
Fund Type | |
Status | |
Amount | $4.31M |
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.